Overview
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver. Prednisone was granted FDA approval on 21 February 1955.
Indication
Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.
Associated Conditions
- Acne Vulgaris
- Acute Exacerbation of Chronic Obstructive Pulmonary Disease
- Acute Gouty Arthritis
- Acute Leukemia
- Aggressive Lymphoma
- Allergic Bronchopulmonary Aspergillosis
- Allergic Conjunctivitis (AC)
- Allergic Rhinitis (AR)
- Allergic corneal marginal ulcers
- Alveolitis, Extrinsic Allergic
- Ankylosing Spondylitis (AS)
- Aspiration Pneumonitis
- Asthma
- Atopic Dermatitis
- Autoimmune Hepatitis
- Bell's Palsy
- Berylliosis
- Bullous dermatitis herpetiformis
- Chorioretinitis
- Congenital Adrenal Hyperplasia (CAH)
- Congenital Hypoplastic Anemia
- Contact Dermatitis
- Disseminated tuberculosis
- Drug hypersensitivity reaction
- Edema of the cerebrum
- Epicondylitis
- Erythroblastopenia
- Giant Cell Arteritis (GCA)
- Hypercalcemia of Malignancy
- Idiopathic Pulmonary Fibrosis (IPF)
- Immune Thrombocytopenia (ITP)
- Iridocyclitis
- Iritis
- Keratitis
- Leukemias
- Loeffler's syndrome
- Lymphoma
- Meningitis caused by Mycobacterium Tuberculosis
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Mycosis Fungoides (MF)
- Ocular Inflammation
- Ophthalmia, Sympathetic
- Optic Neuritis
- Pain caused by Herpes zoster
- Pemphigus
- Pericarditis
- Pneumocystis Jirovecii Pneumonia
- Polymyalgia Rheumatica (PMR)
- Polymyositis
- Posterior Uveitis
- Primary adrenocortical insufficiency
- Psoriatic Arthritis
- Pure Red Cell Aplasia
- Regional Enteritis
- Relapsing Polychondritis
- Rheumatoid Arthritis
- Rheumatoid Arthritis, Juvenile
- Secondary adrenocortical insufficiency
- Secondary thrombocytopenia
- Serum Sickness
- Severe Seborrheic Dermatitis
- Sjogren's Syndrome (SS)
- Solid Organ Transplant Rejection
- Stevens-Johnson Syndrome
- Systemic Lupus Erythematosus
- Takayasu Arteritis
- Thyroid Eye Disease
- Thyroiditis
- Thyrotoxicosis
- Trichinosis
- Ulcerative Colitis
- Uveitis
- Vasculitis
- Acquired immune hemolytic anemia
- Acute Bursitis
- Acute Crohn's Disease (CD)
- Acute Multiple sclerosis exacerbation
- Acute rheumatic carditis
- Anterior eye segment inflammation
- Exfoliative erythroderma
- Fulminating Tuberculosis
- Idiopathic Bronchiolitis obliterans with organizing pneumonia
- Idiopathic eosinophilic pneumonias
- Non-suppurative Thyroiditis
- Severe Psoriasis
- Subacute Bursitis
- Symptomatic Sarcoidosis
- Synovitis of osteoarthritis
- Systemic Dermatomyositis
- Varicella-zoster virus acute retinal necrosis
Research Report
Comprehensive Monograph on Prednisone (DB00635)
[Executive Summary]
Prednisone is a potent, synthetically produced glucocorticoid that has served as a cornerstone of anti-inflammatory and immunosuppressive therapy for over half a century, following its initial FDA approval on February 21, 1955.[1] It functions as a biologically inert prodrug, requiring hepatic conversion to its active metabolite, prednisolone, to exert its therapeutic effects.[1] Its mechanism of action is profound and ubiquitous, involving the binding to glucocorticoid receptors present in nearly every cell type in the body.[3] This interaction leads to complex downstream effects on gene expression, primarily the suppression of pro-inflammatory pathways and the enhancement of anti-inflammatory processes. This broad mechanism underpins Prednisone's remarkable efficacy across an extensive spectrum of clinical conditions, including rheumatologic, respiratory, allergic, hematologic, neoplastic, and autoimmune diseases, as well as in the prevention of organ transplant rejection.[1]
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2025/08/15 | Not Applicable | Recruiting | |||
2025/07/31 | Not Applicable | Not yet recruiting | |||
2025/07/18 | Not Applicable | Not yet recruiting | |||
2025/07/16 | Not Applicable | Not yet recruiting | |||
2025/07/11 | Not Applicable | Not yet recruiting | Samer Gawrieh | ||
2025/06/24 | Phase 2 | Not yet recruiting | |||
2025/06/05 | Phase 2 | Recruiting | |||
2025/05/21 | Phase 3 | Not yet recruiting | |||
2025/05/18 | Phase 1 | Recruiting | |||
2025/05/02 | Phase 2 | Recruiting | Jennifer Amengual |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
A-S Medication Solutions | 50090-0439 | ORAL | 5 mg in 1 1 | 8/19/2022 | |
ANI Pharmaceuticals, Inc. | 70954-061 | ORAL | 50 mg in 1 1 | 2/16/2024 | |
QPharma Inc | 42708-045 | ORAL | 10 mg in 1 1 | 12/8/2023 | |
NCS HealthCare of KY, LLC dba Vangard Labs | 0615-8391 | ORAL | 10 mg in 1 1 | 8/2/2022 | |
Northwind Pharmaceuticals | 51655-763 | ORAL | 2.5 mg in 1 1 | 1/1/2023 | |
A-S Medication Solutions | 50090-1455 | ORAL | 2.5 mg in 1 1 | 1/5/2023 | |
Diect_Rx | 61919-326 | ORAL | 20 mg in 1 1 | 8/7/2019 | |
A-S Medication Solutions | 50090-4784 | ORAL | 20 mg in 1 1 | 4/30/2019 | |
RedPharm Drug, Inc. | 67296-1767 | ORAL | 10 mg in 1 1 | 1/21/2022 | |
RPK Pharmaceuticals, Inc. | 53002-3090 | ORAL | 10 mg in 1 1 | 12/7/2017 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
APO-PREDNISONE TABLET 5 mg | SIN04379P | TABLET | 5 mg | 5/3/1990 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
PREDSONE prednisone 1 mg tablet bottle | 99792 | Medicine | A | 2/23/2004 | |
PANAFCORT prednisone 1 mg tablet bottle | 39879 | Medicine | A | 5/26/1992 | |
SONE prednisone 25 mg tablet bottle | 13470 | Medicine | A | 8/30/1991 | |
predniSONE Tablet 20mg | 400512 | Medicine | A | 12/4/2022 | |
PANAFCORT prednisone 25 mg tablet bottle | 27957 | Medicine | A | 10/21/1991 | |
predniSONE Tablet 10mg | 400511 | Medicine | A | 12/4/2022 | |
PANAFCORT prednisone 5 mg tablet bottle | 27974 | Medicine | A | 10/21/1991 | |
SONE prednisone 5 mg tablet bottle | 56129 | Medicine | A | 7/4/1996 | |
predniSONE Tablet, 5mg | 400510 | Medicine | A | 12/4/2022 |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
PREDNISONE 50 TAB 50MG | PRO DOC LIMITEE | 00607517 | Tablet - Oral | 50 MG | 12/31/1994 |
NU-PREDNISONE | nu-pharm inc | 02239539 | Tablet - Oral | 1 MG | N/A |
TEVA-PREDNISONE | teva canada limited | 00232378 | Tablet - Oral | 50 MG | 12/31/1972 |
APO PREDNISONE TAB 1MG USP | 00598194 | Tablet - Oral | 1 MG | 12/31/1984 | |
DELTASONE 5MG | pharmacia & upjohn inc | 00210188 | Tablet - Oral | 5 MG / TAB | 12/31/1972 |
NU-PREDNISONE | nu-pharm inc | 02239541 | Tablet - Oral | 50 MG | N/A |
METRETON TAB | schering-plough canada inc | 00177091 | Tablet - Oral | 2.5 MG | 12/31/1956 |
JAA PREDNISONE TAB 5MG USP | jaapharm canada inc. | 00868442 | Tablet - Oral | 5 MG | 12/31/1993 |
WINPRED TAB 5MG | valeant canada lp / valeant canada s.e.c. | 00271381 | Tablet - Oral | 5 MG | 12/31/1985 |
JAA PREDNISONE TAB 1MG USP | jaapharm canada inc. | 00868426 | Tablet - Oral | 1.0 MG | 5/15/1993 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
PREDNISONA TARBIS 30 mg COMPRIMIDOS EFG | Tarbis Farma S.L. | 75677 | COMPRIMIDO | Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración | Commercialized |
PREDNISONA TARBIS 10 mg COMPRIMIDOS | Tarbis Farma S.L. | 75641 | COMPRIMIDO | Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración | Commercialized |
PREDNISONA CINFA 5 mg COMPRIMIDOS EFG | Laboratorios Cinfa S.A. | 75647 | COMPRIMIDO | Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración | Commercialized |
PREDNISONA CINFA 30 mg COMPRIMIDOS EFG | Laboratorios Cinfa S.A. | 75676 | COMPRIMIDO | Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración | Commercialized |
PREDNISONA CINFA 2,5 mg COMPRIMIDOS EFG | Laboratorios Cinfa S.A. | 75644 | COMPRIMIDO | Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración | Commercialized |
DACORTIN 2,5 mg COMPRIMIDOS | Laboratorios Ern S.A. | 47863 | COMPRIMIDO | Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración | Commercialized |
PREDNISONA KERN PHARMA 30 mg COMPRIMIDOS EFG | 70108 | COMPRIMIDO | Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración | Commercialized | |
PREDNISONA ALONGA 50 mg COMPRIMIDOS | 58336 | COMPRIMIDO | Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración | Not Commercialized | |
PREDNISONA TARBIS 2,5 mg COMPRIMIDOS EFG | Tarbis Farma S.L. | 75634 | COMPRIMIDO | Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración | Commercialized |
PREDNISONA KERN PHARMA 5 mg COMPRIMIDOS EFG | 70106 | COMPRIMIDO | Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración | Commercialized |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.